New Number of Shares and Votes in Tobii


Stockholm, April 30th, 2015 -- The number of shares and votes in Tobii AB (publ)
has changed as a result of the issue of new shares in connection with the
listing on Nasdaq Stockholm.

Today, the last trading day of the month, there are in total 84,927,883 shares
and votes in the company.

Tobii is required under the Financial Instruments Trading Act to make the
information in this press release public. The information was submitted for
publication at 11.45 a.m. CET on April 30, 2015.

For more information, please contact:

Sara Hyléen, Corporate Communications Director of Tobii, tel: +46 70 9161641,
email: sara.hyleen@tobii.com

About Tobii
Tobii is the global leader in eye tracking. Our vision is a world where all
technology works in harmony with natural human behavior. Tobii has pioneered
research in many fields and enables communication for tens of thousands of
people with special needs. We also focus on changing how people interact with
technology in computers, games and cars. Tobii operates through three business
units: Tobii Dynavox makes specially designed computers that are controlled by
eye movement or touch screens for use by people with special needs due to spinal
cord injuries, CP, ALS or other medical conditions Tobii Pro develops and sells
eye-tracking equipment and services used today by more than 2000 companies and
1500 research institutions, including 49 of the world’s 50 highest ranked
universities. Tobii Tech further advances Tobii’s technology for new volume
markets such as computer games, personal computers and cars. Tobii covers the
global market through its offices in Sweden (headquarters), the USA, China,
Japan, Germany, the UK, and Norway, along with a global network of resellers.
The Group has some 570 employees and has achieved rapid annual growth since it
was founded in 2001.

The Tobii share has been listed since April 24 on the Nasdaq Stockholm Stock
Exchange under the symbol TOBII.

For more information, please visit www.tobii.com.

Attachments

04305466.pdf
GlobeNewswire